Latest News on BLFS

Financial News Based On Company


Advertisement
Advertisement

Form 15-12G BIOLIFE SOLUTIONS INC

https://www.streetinsider.com/SEC+Filings/Form+15-12G+BIOLIFE+SOLUTIONS+INC/27197894.html
BioLife Solutions, Inc. has filed a Form 15-12G with the SEC, certifying the termination of its registration under Section 12(g) and the suspension of its duty to file reports under Sections 13 and 15(d) of the Securities Exchange Act of 1934. This action follows a merger on October 6, 2026, where BioLife Solutions, Inc. became BioLife Solutions, LLC, a direct, wholly-owned subsidiary of Repligen Corporation. The filing indicates that BioLife Solutions, LLC, as the successor by merger, now has only one holder of record.

BIOLIFE SOLUTIONS INC SEC Filing (Oct 16, 2026)

https://www.stocktitan.net/sec-filings/BLFS/15-12g-biolife-solutions-inc-sec-filing-31f8d1982e4f.html
BioLife Solutions, Inc. (BLFS) has filed a Form 15-12G with the SEC, certifying the termination of its registration under Section 12(g) of the Securities Exchange Act of 1934 and the suspension of its duty to file reports. This action follows a merger completed on October 6, 2026, where BioLife Solutions merged into Bravo Merger Sub II, LLC, a wholly-owned subsidiary of Repligen Corporation, and was subsequently renamed BioLife Solutions, LLC. The filing indicates that as of the certification date, there is only one holder of record.

BIOLIFE SOLUTIONS INC SEC Filing (Oct 13, 2026)

https://www.stocktitan.net/sec-filings/BLFS/effect-biolife-solutions-inc-sec-filing-e81df9e47119.html
This article announces an SEC filing for BioLife Solutions Inc. (BLFS) on October 13, 2026, specifically a Notice of Effectiveness (EFFECT) with a neutral filing impact and sentiment. The filing indicates an Effectiveness Date of October 9, 2026, and provides details such as the accession number, submission type, CIK, and file number for the company.

Form EFFECT BIOLIFE SOLUTIONS INC

https://www.streetinsider.com/SEC+Filings/Form+EFFECT+BIOLIFE+SOLUTIONS+INC/27176249.html
This article announces the effectiveness of a Form EFFECT filing by BIOLIFE SOLUTIONS INC with the SEC. The filing has an effectiveness date of October 9, 2026, and is associated with CIK 0000834365 and File Number 333-275645. The article also includes various financial news headlines and market data from StreetInsider.com.

Form 4 BIOLIFE SOLUTIONS INC For: 8 October By Investing.com

https://ng.investing.com/news/stock-market-news/form-4-biolife-solutions-inc-for-8-october-93CH-2728409
This article reports on a Form 4 filing for BioLife Solutions Inc. for October 8th. Form 4 filings are legally required documents submitted to the U.S. Securities and Exchange Commission (SEC) by company insiders, such as officers, directors, and beneficial owners, whenever they buy or sell shares of their company's stock. The article itself contains no further details about the transaction.
Advertisement

Stock awards vested at about 200% of grants for BioLife Solutions (BLFS) CEO before merger dispositions.

https://www.stocktitan.net/sec-filings/BLFS/form-4-biolife-solutions-inc-insider-trading-activity-333da91e1f25.html
BioLife Solutions Inc. CEO Roderick de Greef reported significant stock transactions on October 6, 2026, including the acquisition of 225,670 and 237,460 restricted shares that vested at approximately 200% of the granted amount just before a merger. De Greef subsequently disposed of 826,454 shares in connection with the merger, where each BioLife share converted into $11.25 cash and 0.1442 Repligen shares. Additionally, 364,872 shares were withheld for tax obligations related to the vesting.

BioLife Solutions Shareholders Approve Repligen Merger Agreement

https://es.tradingview.com/news/marketbeat:e9eb92c68094b:0-biolife-solutions-shareholders-approve-repligen-merger-agreement/
BioLife Solutions shareholders have approved the merger agreement with Repligen Corporation, clearing a major hurdle for the proposed transaction. The approval was secured at a special meeting held virtually on October 5, 2026, where stockholders also approved executive compensation related to the merger. Final voting results will be disclosed in an upcoming Form 8-K filing with the SEC.

Form 4 BIOLIFE SOLUTIONS INC For: 8 October By Investing.com

https://ng.investing.com/news/stock-market-news/form-4-biolife-solutions-inc-for-8-october-93CH-2728408
This article from Investing.com reports on the filing of a Form 4 for BIOLIFE SOLUTIONS INC, specifically for October 8th. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a change in the beneficial ownership of a company's securities by an insider. The article itself is very brief, mainly serving as a notice of the filing rather than providing detailed analysis.

After a merger disposition of 26,857 shares, BioLife Solutions (BLFS) director reports zero direct shares.

https://www.stocktitan.net/sec-filings/BLFS/form-4-biolife-solutions-inc-insider-trading-activity-2a61272d59b6.html
BioLife Solutions director Amy DuRoss disposed of 26,857 common shares following a merger completed on October 6, 2026, resulting in zero direct holdings. Each BioLife Solutions share was converted into $11.25 in cash and 0.1442 shares of Repligen common stock. This transaction is documented in a Form 4 SEC filing, detailing the merger terms and the change in her beneficial ownership.

Awards vest at about 200% as BioLife Solutions (BLFS) CFO disposes of shares in merger.

https://www.stocktitan.net/sec-filings/BLFS/form-4-biolife-solutions-inc-insider-trading-activity-cfc03b2f0a44.html
BioLife Solutions (BLFS) CFO Troy Wichterman disposed of 256,000 shares in connection with a merger that became effective on October 6, 2026. Prior to the merger, Wichterman acquired 76,204 and 62,300 shares under restricted-stock awards which vested at approximately 200% of the number of shares granted, based on specific performance periods. The merger converted each BioLife common share into $11.25 in cash and 0.1442 Repligen common shares.
Advertisement

A director disposes of 13,871 BioLife Solutions (BLFS) shares in a merger, leaving no direct shares.

https://www.stocktitan.net/sec-filings/BLFS/form-4-biolife-solutions-inc-insider-trading-activity-eeb6f58cca4e.html
BioLife Solutions director Catherine Coste disposed of 13,871 shares on October 6, 2026, as part of a merger agreement. Following this transaction, her direct holdings in BioLife Solutions (BLFS) are 0 shares. The merger terms stipulated that each BioLife common share converted into the right to receive $11.25 in cash and 0.1442 Repligen common shares.

After disposing of 57,995 merger shares, BioLife Solutions (BLFS) director Ellingson holds none directly.

https://www.stocktitan.net/sec-filings/BLFS/form-4-biolife-solutions-inc-insider-trading-activity-685c664228a8.html
BioLife Solutions director Rachel Ellingson disposed of 57,995 common shares on October 6, 2026, as part of a merger with Repligen. Each BioLife share was converted into $11.25 in cash and 0.1442 shares of Repligen common stock. Following the transaction, Ellingson directly holds zero shares of BioLife Solutions.

After disposing of 53,156 merger shares, BioLife Solutions (BLFS) director Goswami reports no direct holdings.

https://www.stocktitan.net/sec-filings/BLFS/form-4-biolife-solutions-inc-insider-trading-activity-3e820a71d5c1.html
BioLife Solutions director Joydeep Goswami reported the disposition of 53,156 common shares on October 6, 2026, in connection with the company's merger with Repligen Corporation. Following this transaction, Goswami holds no direct shares in BioLife Solutions. Each outstanding BioLife common share was converted into the right to receive $11.25 in cash and 0.1442 Repligen common shares as part of the merger agreement.

BioLife Solutions, Inc.(NasdaqCM: BLFS) dropped from S&P 600 Health Care

https://www.marketscreener.com/news/biolife-solutions-inc-nasdaqcm-blfs-dropped-from-s-p-600-health-care-ce785ddedf8bf424
BioLife Solutions, Inc. (NasdaqCM: BLFS), a developer and supplier of cell processing tools for the cell and gene therapy market, has been removed from the S&P 600 Health Care index. This announcement follows recent corporate changes, including the resignation of its CFO and CEO, and the completion of its acquisition by Repligen Corporation. The company's stock, trading on Nasdaq, saw a 3.51% increase on the day of the news, despite the index removal.

Resale offerings end at BioLife Solutions (BLFS), after prior registration of up to 927,165 shares.

https://www.stocktitan.net/sec-filings/BLFS/pos-am-biolife-solutions-inc-sec-filing-90d15d84c2de.html
BioLife Solutions, Inc. (BLFS) has terminated its resale stock offerings and deregistered all unsold securities that were part of a previous registration statement for up to 927,165 shares of common stock. This action follows a two-step merger completed on October 6, 2026, where BioLife Solutions became BioLife Solutions, LLC, a wholly owned subsidiary of Repligen Corporation. The termination aligns with undertakings to remove unsold securities after the offering's conclusion.
Advertisement

Repligen Completes BioLife Solutions Acquisition, Expanding Cell Therapy Platform

https://www.citybiz.co/article/915015/repligen-completes-biolife-solutions-acquisition-expanding-cell-therapy-platform/
Repligen Corporation has finalized its acquisition of BioLife Solutions, significantly expanding its presence in the cell and gene therapy market. This strategic move integrates BioLife's biopreservation and cell processing products, including the widely used CryoStor, into Repligen's portfolio. The acquisition is expected to create recurring consumables revenue and leverage Repligen's global infrastructure for broader market reach in the rapidly growing cell therapy sector.

Voluntary withdrawal requirements are met as Nasdaq moves to delist BioLife Solutions (Nasdaq: BLFS).

https://www.stocktitan.net/sec-filings/BLFS/25-nse-biolife-solutions-inc-sec-filing-84721e50e31d.html
Nasdaq has issued a Form 25 notification regarding the delisting of BioLife Solutions Inc. (BLFS) common stock. This action indicates that Nasdaq has complied with its rules to remove the class from listing, and BioLife Solutions has met the requirements for voluntary withdrawal. The notification certifies that Nasdaq has reasonable grounds for this filing, as detailed in the SEC filing.

Form 25-NSE BIOLIFE SOLUTIONS INC Filed by: Nasdaq Stock Market LLC

https://www.streetinsider.com/SEC+Filings/Form+25-NSE+BIOLIFE+SOLUTIONS+INC+Filed+by%3A+Nasdaq+Stock+Market+LLC/27153420.html
This article reports that a Form 25-NSE filing for BioLife Solutions Inc. was submitted by Nasdaq Stock Market LLC. The filing was made on October 6, 2026, and includes attachments in XML and TXT formats.

[8-K] BIOLIFE SOLUTIONS INC Reports Material Event

https://www.stocktitan.net/sec-filings/BLFS/8-k-biolife-solutions-inc-reports-material-event-d761854c4368.html
BIOLIFE SOLUTIONS INC (BLFS) has filed an 8-K report detailing its acquisition by Repligen Corporation, effective October 6, 2026. As a result, BioLife Solutions ceased to exist as a separate legal entity, and its common stock will be delisted from Nasdaq. Shareholders received $11.25 in cash plus 0.1442 Repligen shares for each BioLife share.

Repligen Completes Acquisition of BioLife Solutions

https://www.globenewswire.com/news-release/2026/10/06/3375610/0/en/repligen-completes-acquisition-of-biolife-solutions.html
Repligen Corporation has completed the acquisition of BioLife Solutions, a move expected to expand Repligen's presence in the cell therapy market by integrating BioLife's cell processing tools and services. The acquisition aims to enhance support for customers in the cell therapy workflow, combining BioLife's differentiated biopreservation media portfolio with Repligen's global reach. BioLife stockholders received a combination of cash and Repligen common stock as part of the transaction.
Advertisement

BioLife Solutions Received Notice of Delisting

https://www.tradingview.com/news/tradingview:317acf35e93f4:0-biolife-solutions-received-notice-of-delisting/
BioLife Solutions (BLFS) received a notice of delisting from Nasdaq. This action followed the completion of its merger with Repligen, which led the company to cease meeting Nasdaq listing requirements. Trading of BLFS stock was halted after-market on October 5, 2026, and suspended as of the close on October 6, 2026, with plans to officially delist and terminate reporting obligations by filing Forms 25 and 15.

Freshworks joins S&P SmallCap 600 as BioLife So...

https://pluang.com/en/news-feed/freshworks-bergabung-di-sp-smallcap-600
Freshworks Inc. will be added to the S&P SmallCap 600 index on October 8, 2026, replacing BioLife Solutions Inc., which is being acquired by Repligen Corp. Freshworks has a market cap of $3.33 billion and its stock price recently rose by 7.75%, though investor sentiment appears mixed with 100% sell interest on Pluang. This change reflects ongoing market adjustments due to M&A activities.

BioLife Solutions, Inc. (NASDAQ:BLFS) Stock Has Consensus Target Price of $31.38 According to Brokerages

https://www.marketbeat.com/instant-alerts/consensus-biolife-solutions-inc-nasdaq-blfs-stock-has-consensus-target-price-of-3138-according-to-brokerages-2026-10-05/
BioLife Solutions, Inc. (NASDAQ:BLFS) has received a consensus "Hold" rating from eleven analysts, with an average 12-month price target of $31.38. Despite this, the stock opened at $37.30, trading above its average price objective. The company recently surpassed earnings expectations, reporting $0.91 EPS against a $0.03 consensus and revenues of $28.47 million, exceeding the $27.80 million forecast.

[425] BIOLIFE SOLUTIONS INC Business Combination Communication | BLFS SEC Filing - Form 425

https://www.stocktitan.net/sec-filings/BLFS/425-biolife-solutions-inc-business-combination-communication-d2caa46be60e.html
This SEC Form 425 filing details the business combination between BioLife Solutions Inc. (BLFS) and Repligen Corporation, where Repligen will acquire BioLife for cash and Repligen common shares. The merger is subject to BioLife stockholder approval and is facing two shareholder lawsuits alleging misrepresentation in the proxy statement. The filing includes supplemental disclosures to address these concerns and provides updated information regarding executive compensation and severance packages post-merger.

Two parties report shared voting power over more than 5% of BioLife Solutions (BLFS) shares.

https://www.stocktitan.net/sec-filings/BLFS/schedule-13g-biolife-solutions-inc-passive-investment-disclosure-5-104b2ffc084c.html
Glazer Capital, LLC and Paul J. Glazer have reported shared beneficial ownership of 2,685,520 common shares, representing 5.49% of BioLife Solutions (BLFS). This Schedule 13G filing indicates that both parties have shared voting and dispositive power over these shares, with Glazer Capital acting as the investment manager for the funds holding them. Additionally, Glazer Capital Enhanced Master Fund, Ltd. has the right to receive or direct proceeds from the sale of over 5% of BioLife's outstanding common stock.
Advertisement

BioLife Solutions, Inc. (BLFS) Stock Price, News, Quote & History

https://ca.finance.yahoo.com/quote/BLFS/
This Yahoo Finance article provides a detailed overview of BioLife Solutions, Inc. (BLFS), including its current stock price, trading activity, key financial metrics, and company profile. It highlights the company's focus on bioproduction products and services for the cell and gene therapy industry, along with performance benchmarks against the S&P 500 and analyst insights.

BioLife Solutions (BLFS) CEO uses shares to cover taxes

https://www.stocktitan.net/sec-filings/BLFS/form-4-biolife-solutions-inc-insider-trading-activity-718fd2ecd3f1.html
BioLife Solutions CEO, Roderick De Greef, had 2,775 shares of company common stock withheld to satisfy tax obligations related to vested restricted stock units. This transaction, which occurred on September 18, 2026, at $36.69 per share, was a tax withholding event and not a market sale. Following this, De Greef directly holds 728,196 shares of BLFS common stock.

BioLife Solutions (BLFS) withholds 564 insider shares for taxes

https://www.stocktitan.net/sec-filings/BLFS/form-4-biolife-solutions-inc-insider-trading-activity-4f6a1ec79d1f.html
BioLife Solutions' EVP & Chief Scientific Officer, Mathew Aby J., had 564 shares of common stock withheld on September 18, 2026, to cover tax obligations from restricted stock unit vesting. The shares were valued at $36.69 each, and after this transaction, Mr. Aby J. directly holds 387,269 shares of BLFS. This withholding was not part of a Rule 10b5-1 trading plan.

Biolife Solutions stock hits 52-week high at $38.10

https://www.investing.com/news/company-news/biolife-solutions-stock-hits-52week-high-at-3810-93CH-4911250
BioLife Solutions (BLFS) stock recently hit a 52-week high of $38.10, driven by a 97% surge over the last six months, although it is now considered overvalued by InvestingPro. The company's financial health is rated "GREAT," and it is undergoing a merger with Repligen Corporation, which will acquire BioLife for $11.25 in cash and 0.1442 shares of Repligen stock per BioLife share. Following the merger announcement, TD Cowen downgraded BioLife Solutions from Buy to Hold, adjusting its price target to $31 per share.

Tidal Investments LLC Buys Shares of 29,012 BioLife Solutions, Inc. $BLFS

https://www.marketbeat.com/instant-alerts/filing-tidal-investments-llc-buys-shares-of-29012-biolife-solutions-inc-blfs-2026-09-21/
Tidal Investments LLC has acquired 29,012 shares of BioLife Solutions, Inc. (NASDAQ:BLFS) valued at approximately $819,000, establishing a 0.06% stake in the company. Institutional investors now collectively own 93.24% of BioLife Solutions. The company recently reported strong quarterly results, exceeding analyst expectations for both revenue and EPS, though analysts maintain a "Hold" rating with a consensus price target of $31.38.
Advertisement

Squarepoint Ops LLC Purchases New Position in BioLife Solutions, Inc. $BLFS

https://www.marketbeat.com/instant-alerts/filing-squarepoint-ops-llc-purchases-new-position-in-biolife-solutions-inc-blfs-2026-09-13/
Squarepoint Ops LLC has acquired a new stake in BioLife Solutions, Inc. (NASDAQ:BLFS), purchasing 132,942 shares valued at $3.75 million. This move comes as institutional investors now own 93.24% of the company, despite several analysts downgrading the stock to "Hold" or "Neutral" with revised price targets. BioLife Solutions recently surpassed earnings and revenue expectations, but its stock is trading near its 52-week high, with an average analyst target price of $31.38.

BioLife Solutions EVP Aby J. Mathew Withholds 627 Shares for RSU Tax on September 8, 2026

https://kalkinemedia.com/us/news/announcements/biolife-solutions-evp-aby-j-mathew-withholds-627-shares-for-rsu-tax-on-september-8-2026
BioLife Solutions EVP and Chief Scientific Officer, Aby J. Mathew, withheld 627 common stock shares valued at $35.38 each on September 8, 2026, to cover tax obligations related to the release of restricted stock units (RSUs). This transaction, filed on a Form 4, indicates that Mathew directly holds 387,833 common stock shares after the withholding. The filing confirms that the transaction was for tax purposes and not executed under a Rule 10b5-1(c) trading plan.

BioLife Solutions merger with Repligen advances as antitrust waiting period ends

https://m.investing.com/news/sec-filings/biolife-solutions-merger-with-repligen-advances-as-antitrust-waiting-period-ends-93CH-4895110?ampMode=1
BioLife Solutions announced that the Hart-Scott-Rodino Antitrust Improvements Act waiting period for its proposed acquisition by Repligen Corporation has expired, satisfying a key merger condition. Repligen will acquire BioLife for $11.25 in cash and 0.1442 shares of Repligen common stock per BioLife share. The merger remains subject to BioLife stockholder approval, with a special meeting scheduled for October 5, 2026.

BioLife Solutions, Inc. (NASDAQ:BLFS) Receives Average Recommendation of "Hold" from Analysts

https://www.marketbeat.com/instant-alerts/consensus-biolife-solutions-inc-nasdaq-blfs-receives-average-recommendation-of-hold-from-analysts-2026-09-10/
Analysts have issued an average "Hold" recommendation for BioLife Solutions (NASDAQ:BLFS), with a consensus 12-month price target of $31.38, which is below the current stock price of $34.93. Recent downgrades from several brokerages reflect this cautious outlook, despite the company exceeding its latest quarterly earnings and revenue expectations. Institutional investors hold a significant majority of the company's shares.

Form 8K BioLife Solutions Inc For: 10 September By Investing.com

https://ng.investing.com/news/stock-market-news/form-8k-biolife-solutions-inc-for-10-september-93CH-2690710
This article announces the filing of a Form 8K by BioLife Solutions Inc. on September 10. The brief update from Investing.com is a standard notification about corporate filings. No specific details about the content of the 8K are provided within this particular news item.
Advertisement

BioLife Solutions Inc. (BLFS) Key Financial Ratios – Valuation, Profitability & More

https://www.valueresearchonline.com/stocks/291309/biolife-solutions-inc-blfs/key-ratios/
This article provides a detailed analysis of BioLife Solutions Inc. (BLFS) key financial ratios, covering valuation, profitability, growth, solvency, and operating efficiency. It presents both quarterly and annual data, including comparisons with peer medians. The report highlights BLFS's performance in revenue, net profit, return on equity, and other critical financial metrics.

BLFS Stock Alert: Halper Sadeh LLC is Investigating Whether BioLife Solutions, Inc. is Obtaining a Fair Price for its Shareholders

https://natlawreview.com/press-releases/blfs-stock-alert-halper-sadeh-llc-investigating-whether-biolife-solutions
Halper Sadeh LLC, an investor rights law firm, is investigating the proposed sale of BioLife Solutions, Inc. (NASDAQ: BLFS) to Repligen Corporation for $11.25 per share in cash and 0.1442 shares of Repligen common stock. The firm is examining whether BioLife's board failed to secure the best possible price for shareholders, conducted a fair sales process, and disclosed all material information. Halper Sadeh LLC encourages BioLife shareholders to contact them to discuss their rights and options.

BLFS Stock Alert: Halper Sadeh LLC is Investigating Whether BioLife Solutions, Inc. is Obtaining a Fair Price for its Shareholders

https://www.financialcontent.com/article/bizwire-2026-8-29-blfs-stock-alert-halper-sadeh-llc-is-investigating-whether-biolife-solutions-inc-is-obtaining-a-fair-price-for-its-shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating the proposed sale of BioLife Solutions, Inc. (NASDAQ: BLFS) to Repligen Corporation for $11.25 per share in cash and 0.1442 shares of Repligen common stock. The firm is examining whether BioLife's board violated federal securities laws or breached fiduciary duties by potentially failing to secure the best price, ensure a fair sales process, or disclose all material information. Shareholders are encouraged to contact Halper Sadeh LLC to discuss their rights.

BioLife Solutions (NASDAQ:BLFS) Reaches New 52-Week High - Still a Buy?

https://www.marketbeat.com/instant-alerts/biolife-solutions-nasdaqblfs-reaches-new-52-week-high-still-a-buy-2026-08-24/
BioLife Solutions (NASDAQ:BLFS) recently reached a new 52-week high of $38.10, with a market capitalization of $1.86 billion, despite analysts maintaining a "Hold" rating and an average price target of $31.38. The company reported a significant earnings beat of $0.91 per share against an estimate of $0.03, with revenues of $28.47 million. Institutional investors hold a substantial 93.24% of the stock, with the California State Teachers’ Retirement System notably increasing its position.

238,521 Shares in BioLife Solutions, Inc. $BLFS Acquired by Ranger Investment Management L.P.

https://www.marketbeat.com/instant-alerts/filing-238521-shares-in-biolife-solutions-inc-blfs-acquired-by-ranger-investment-management-lp-2026-08-24/
Ranger Investment Management L.P. acquired a new position of 238,521 shares in BioLife Solutions, Inc. (NASDAQ:BLFS) valued at approximately $6.7 million during the second quarter, representing 0.49% of the company's stock. Other institutional investors also adjusted their holdings, contributing to institutional ownership of 93.24%. Despite opening near its 52-week high, BioLife Solutions holds a consensus "Hold" rating from analysts with an average price target of $31.38, following several recent downgrades.
Advertisement

Bank of America Corp DE Increases Stake in BioLife Solutions, Inc. $BLFS

https://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-increases-stake-in-biolife-solutions-inc-blfs-2026-08-21/
Bank of America Corp DE significantly increased its stake in BioLife Solutions, Inc. (NASDAQ:BLFS) by 73.4% in the first quarter, now owning 904,103 shares valued at approximately $17.25 million. Other institutional investors also adjusted their positions in the medical equipment provider, which recently reported strong quarterly earnings, beating consensus estimates. Despite several analyst downgrades to "Hold," institutional investors collectively hold 93.24% of BLFS shares.

Summit Creek Advisors LLC Acquires New Position in BioLife Solutions, Inc. $BLFS

https://www.marketbeat.com/instant-alerts/filing-summit-creek-advisors-llc-acquires-new-position-in-biolife-solutions-inc-blfs-2026-08-19/
Summit Creek Advisors LLC has acquired a new position in BioLife Solutions, Inc. (NASDAQ:BLFS) during the second quarter, purchasing 180,544 shares valued at approximately $5.1 million, making BLFS its 28th largest position. Institutional investors and hedge funds collectively own 93.24% of the company, though analyst sentiment remains mixed with an average "Hold" rating. BioLife Solutions recently reported strong quarterly EPS of $0.91, significantly exceeding estimates, while facing insider selling from a major shareholder.

Diamond Hill Capital Management LLC Investment Advisor Acquires New Stake in BioLife Solutions, Inc. $BLFS

https://www.marketbeat.com/instant-alerts/filing-diamond-hill-capital-management-llc-investment-advisor-acquires-new-stake-in-biolife-solutions-inc-blfs-2026-08-18/
Diamond Hill Capital Management LLC Investment Advisor has acquired a new stake of 153,887 shares in BioLife Solutions, Inc. (NASDAQ:BLFS), valued at approximately $4.35 million. This purchase represents 0.31% of BioLife Solutions, with institutional investors now owning 93.24% of the company. Despite BioLife Solutions beating analysts' EPS and revenue estimates in its latest quarterly report, the consensus analyst rating for the stock has shifted to "Hold" with a target price of $31.38.

Short Interest in BioLife Solutions, Inc. (NASDAQ:BLFS) Rises By 59.1%

https://www.marketbeat.com/instant-alerts/short-interest-in-biolife-solutions-inc-nasdaqblfs-rises-by-591-2026-08-18/
Short interest in BioLife Solutions (NASDAQ:BLFS) surged by 59.1% in July, reaching 4.54 million shares, which represents 9.5% of its outstanding shares. This increase comes as analysts have become more cautious, with several downgrading the stock to "Hold" or "Neutral" and reducing price targets to around $31. Despite these concerns, BioLife Solutions recently surpassed quarterly earnings and revenue expectations.

Biolife Solutions stock hits 52-week high at 35.36 USD

https://www.investing.com/news/company-news/biolife-solutions-stock-hits-52week-high-at-3536-usd-93CH-4863833
BioLife Solutions Inc. (BLFS) has reached a new 52-week high of $35.36, representing a significant surge of nearly 98% from its 52-week low, driven by strong investor confidence. Despite this, InvestingPro data suggests the stock is currently in overbought territory and appears overvalued according to its Fair Value analysis. Additionally, TD Cowen recently downgraded BioLife Solutions to a Hold rating following Repligen's announcement to acquire the company for $31 per share.
Advertisement

BioLife’s Sharp Swing To Profit Might Change The Case For Investing In BioLife Solutions (BLFS)

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-blfs/biolife-solutions/news/biolifes-sharp-swing-to-profit-might-change-the-case-for-inv
BioLife Solutions (BLFS) reported a significant turnaround in Q2 2026, swinging from a net loss to a net income of US$45.10 million and improving EPS from a loss of US$0.32 to earnings of US$0.92. This sharp increase in profitability, coupled with the pending US$1.6 billion acquisition by Repligen, could reshape the company's investment profile. However, investors should also consider the business's reliance on a concentrated customer base and the long-term demand for cell and gene therapy tools.

Roubaix Capital, LLC's BioLife Solutions Inc(BLFS) Holding History

https://www.gurufocus.com/guru-portfolio/Roubaix%20Capital,%20LLC/BLFS
This article details Roubaix Capital, LLC's investment history in BioLife Solutions Inc (BLFS). As of June 30, 2026, Roubaix Capital held over 309,000 shares of BLFS, valued at $8.74 million, representing 3.14% of their portfolio. The firm has made multiple purchases and sales of BLFS since 2019, resulting in an estimated gain of $4.38 million.

BioLife Solutions, Inc. (NASDAQ:BLFS) Given Average Recommendation of "Hold" by Brokerages

https://www.marketbeat.com/instant-alerts/biolife-solutions-inc-nasdaqblfs-given-average-recommendation-of-hold-by-brokerages-2026-08-16/
BioLife Solutions (NASDAQ:BLFS) has received an average "Hold" recommendation from brokerages, with the majority of analysts issuing a hold rating. The company recently reported strong quarterly earnings, beating analyst estimates for both EPS and revenue. Despite positive institutional investor activity, insiders have sold a significant number of shares in the last quarter.

BioLife Solutions, Inc. (BLFS) Stock Forecasts

https://ca.finance.yahoo.com/research/reports/ARGUS_6004_QuantitativeReport_1786492800000
Argus has raised its target price for BioLife Solutions Inc. (BLFS) to $37.00. The company, a life sciences firm, specializes in bioproduction products and services aimed at enhancing quality and mitigating risks in biologic manufacturing, distribution, and transportation within the cell and gene therapy industry. This update suggests a positive outlook for BLFS by Argus.

BioLife Solutions (NASDAQ:BLFS) Hits New 12-Month High - Time to Buy?

https://www.marketbeat.com/instant-alerts/biolife-solutions-nasdaqblfs-hits-new-12-month-high-time-to-buy-2026-08-11/
BioLife Solutions (NASDAQ:BLFS) recently hit a new 52-week high of $34.93, trading nearly flat at $34.64. The company reported strong quarterly earnings of $0.91 per share, significantly beating the consensus estimate of $0.03, and revenue of $28.47 million, exceeding expectations. Despite insider selling activity totaling $28.1 million over the last quarter, institutional investors hold a substantial 93.24% stake in the company, with analyst sentiment generally mixed, holding a consensus "Hold" rating and a target price below the current share price.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement